美国旧金山和中国苏州2025年1月3日 /美通社/ -- 信达生物制药集团（香港联交所股票代码：01801），一家致力于研发、生产和 ...

“New treatment options continue to be needed for patients with ROS1 fusion-positive NSCLC that support important clinical goals, including achieving durable therapeutic responses,” said ...

The committee recommended that the drug be approved for the treatment of adults with ROS1-positive advanced ... solid tumors expressing a NTRK gene fusion, according to a statement.